Market Challenges And Opportunities

India Coronary Stents Market – Driver

Increasing prevalence of coronary heart disease

Prevalence of Coronary heart diseases have been increasing in India. For instance, according to article published in 2020 at Medical Journal Armed Forces India, age-standardized cardiovascular disease death rate in India is much higher (272 per 100,000 population) than that of global average (235 per 100,000 population). According to data published in 2021 on "Accidental Deaths & Suicides in India" (ADSI) compiled by the National Crime Records Bureau (NCRB), the number of deaths due to heart attacks in India has remained consistently over 25,000 in the 2020-2021, and over 28,000 in the last three years, out of which 70% Of Heart Attack Deaths Occurred In 30-60 Age Group.

Addition of coronary stent in the list of essential medicines

India coronary stent market is expected to witness significant growth due to addition of coronary stents in essential medicine list by the government authority of India. For instance, in November, 2022, The Union health ministry of India announced the inclusion of coronary stents in the National List of Essential Medicines, 2022, which will make coronary stents more affordable in India. National list of essential medicine (NLEM) is a list released by Ministry of Heath and Family Welfare. The medicines listed in the NLEM are sold below a price ceiling fixed by the National Pharmaceutical Pricing Authority.

Launch of new products by key market players to expand product portfolio

Launch of new products can drive the growth of India Coronary Stent Market. For instance, in April 19, 2022, Translumina, an India-based company has announced the launch of VIVO ISAR, its latest generation dual drug polymer-free coated stent (DDCS), in various International markets including Europe. VIVO ISAR is a major breakthrough in drug eluting stent technology (DES) as it proves that synthetic polymers can be removed from a DES without compromising the efficacy of the DES.

India Coronary Stents Market: Restraints

Product recalls

Three multinational stent makers Abbott, Medtronic and Boston Scientific Corporation have filed applications with India’s drug pricing regulator to withdraw their new generation stents from the country, due to revised stent pricing regime in India. The decision came after two months of decision by National Pharmaceutical Pricing Authority (NPPA) to reduce the prices of cardiac stents in India by over 75%.

Side effects and adverse events

Ischemic adverse events related to coronary stenting including ischemia-driven target lesion revascularization and stent thrombosis are also expected to hamper growth of the market.

As mentioned above, patients suffering from adverse effect due to coronary stent will take a longer period of time to resume their normal activities. All patients may notice a few complications and side-effects and should seek immediate medical attention in case they experience: